Last reviewed · How we verify

DTPw-HBV/Hib

GlaxoSmithKline · Phase 3 active Biologic

DTPw-HBV/Hib is a Combination vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and children. Also known as: GSK Biologicals' diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type b vaccine.

DTPw-HBV/Hib is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b.

DTPw-HBV/Hib is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b. Used for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and children.

At a glance

Generic nameDTPw-HBV/Hib
Also known asGSK Biologicals' diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type b vaccine
SponsorGlaxoSmithKline
Drug classCombination vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease Prevention
PhasePhase 3

Mechanism of action

This pentavalent vaccine contains inactivated diphtheria and tetanus toxoids, acellular pertussis antigens, hepatitis B surface antigen, and Haemophilus influenzae type b polysaccharide conjugate. Upon administration, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory cells against these five pathogens. The vaccine is designed for primary immunization and booster doses in infants and young children.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTPw-HBV/Hib

What is DTPw-HBV/Hib?

DTPw-HBV/Hib is a Combination vaccine drug developed by GlaxoSmithKline, indicated for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and children.

How does DTPw-HBV/Hib work?

DTPw-HBV/Hib is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b.

What is DTPw-HBV/Hib used for?

DTPw-HBV/Hib is indicated for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and children.

Who makes DTPw-HBV/Hib?

DTPw-HBV/Hib is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is DTPw-HBV/Hib also known as anything else?

DTPw-HBV/Hib is also known as GSK Biologicals' diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type b vaccine.

What drug class is DTPw-HBV/Hib in?

DTPw-HBV/Hib belongs to the Combination vaccine class. See all Combination vaccine drugs at /class/combination-vaccine.

What development phase is DTPw-HBV/Hib in?

DTPw-HBV/Hib is in Phase 3.

What are the side effects of DTPw-HBV/Hib?

Common side effects of DTPw-HBV/Hib include Injection site pain, redness, or swelling, Fever, Irritability or fussiness, Drowsiness.

Related